Scancell Holdings plc
LSE:SCLP

Jigglypop Analysis For Scancell Holdings plc 🤓

Scancell Holdings (GBp 11.7) is pressing its 52‑week ceiling (12.5) and sits comfortably above its 50/200‑day averages, after a 14.7% one‑month surge. That profile, plus clinical-stage status and widening losses, puts this squarely in “speculative” territory rather than a value play. Momentum reflects July Phase II SCOPE data showing iSCIB1+ outperformance in HLA‑targeted melanoma and management’s move toward a registrational study. Insider alignment helps—Vulpes Testudo, linked to NED Martin Diggle, added shares—while cash runway into H2‑2026 underpins near‑term development. With a c. £121m market cap, investors are paying up for pipeline optionality across SCIB1/iSCIB1+, Modi‑1/2 and GlyMab/AvidiMab platforms. Near the top of the 52‑week range, upside hinges on clinical catalysts; setbacks could retrace quickly. AGM on 30 October frames timelines.

About Scancell Holdings plc 👋

Scancell Holdings plc is a clinical-stage biopharmaceutical company that discovers and develops immunotherapies to treat cancer in the United Kingdom. Its product pipeline includes SCIB1/iSCIB1+, now in Phase II for melanoma, and SC134, an antibody targeting small cell lung cancer. It is also advancing Modi-1, an active peptide immunotherapy in Phase II trials for solid tumours, including renal, head and neck, ovarian, and triple-negative breast cancers; and Modi-2, which targets stress-induced post-translational modifications such as homocitrullination. In addition, the company offers the GlyMab platform, which generates high-affinity, tumour-specific monoclonal antibodies (mAb) against glycans over-expressed on cancer cells, and AvidiMab, which promotes receptor clustering to enhance immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, United Kingdom.